{"id":"NCT01139450","sponsor":"Fougera Pharmaceuticals Inc.","briefTitle":"Study of 0417 Ointment in the Treatment of Atopic Dermatitis","officialTitle":"Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Study of 0417 Ointment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2010-06-08","resultsPosted":"2014-09-30","lastUpdate":"2014-10-09"},"enrollment":899,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"0417","otherNames":[]},{"type":"DRUG","name":"Vehicle of 0417 test product","otherNames":[]},{"type":"DRUG","name":"Tacrolimus Ointment 0.03%","otherNames":[]}],"arms":[{"label":"Test","type":"EXPERIMENTAL"},{"label":"Reference","type":"ACTIVE_COMPARATOR"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The aim of this trial is to assess the efficacy of 0417 Ointment in the Treatment of Atopic Dermatitis.\n\nTreatment medication will be administered as follows: Apply a thin layer of ointment to affected skin areas twice daily and rub in gently and completely. Study medication will be applied twice a day, approximately 12 hours apart, for approximately 4 weeks.","primaryOutcome":{"measure":"Incidence of Success Based on the Investigator's Global Evaluation at the End of Treatment","timeFrame":"4 weeks","effectByArm":[{"arm":"Test","deltaMin":123,"sd":null},{"arm":"Reference","deltaMin":130,"sd":null},{"arm":"Vehicle","deltaMin":86,"sd":null}],"pValues":[]},"eligibility":{"minAge":"8 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":302},"commonTop":["Application site irritation","Dermatitis atopic"]}}